Insys Therapeutics’ (INSY) product pipeline includes cannabidiol oral solution and dronabinol inhalation. It also includes naloxone and epinephrine nasal sprays, buprenorphine and naloxone spray, and buprenorphine sublingual spray.
The above chart compares changes in analysts’ recommendations since January 2018.
Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That shows a 12-month target price of $9.60 compared to its price of $9.90 on October 3.
There are five analysts tracking Insys Therapeutics stock. Two of them have recommended a “strong buy,” two have recommended a “buy,” and one has recommended a “sell.” The consensus rating is 2.0, which represents a “strong buy” for value investors.
The market capitalization for Insys Therapeutics is ~$4.6 billion as of October 4.
The total number of Insys shares outstanding is ~74.2 million. Of those, free float shares are ~26.8 million, or 36.1% of the total outstanding shares. Institutions hold ~21.9% of the total shares, while strategic entities own ~63.9%.
The top ten shareholders hold 80.4% of Insys Therapeutics’ total shares. John N. Kapoor Trust is the largest shareholder with 42.4 million shares, or 57.2% of the total shares.
Kapoor Children’s 1992 Trust holds 4.56 million shares, or 6.1% of Insys Therapeutics’ total shares. OrbiMed Advisors holds 3.51 million shares, or 4.7% of the total shares.
The iShares Micro-Cap ETF (IWC) holds 0.1% of its total investments in Insys Therapeutics (INSY), 0.3% in Tabula Rasa HealthCare (TRHC), 0.3% in Vanda Pharmaceuticals (VNDA), and 0.3% in Biohaven Pharmaceutical Holding (BHVN).